NCT00521404View on ClinicalTrials.gov

Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

August 15, 2007

Primary Completion Date

August 20, 2010

Study Completion Date

August 20, 2010

Conditions
Pancreatic Cancer
Interventions
DRUG

CS-1008 (humanized anti-DR5 antibody)

CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.

DRUG

gemcitabine

Gemcitabine - 1000mg/meter sq

Trial Locations (12)

30084

Georgia Cancer Specialists, Tucker

Unknown

Birmingham

Washington D.C.

Fort Myers

Atlanta

Decatur

Minneapolis

Cincinnati

Chattanooga

Nashville

Temple

Richmond

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY